Venclexta
E697099
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
small molecule inhibitor ⓘ targeted cancer therapy ⓘ |
| administrationRequirement |
requires dose ramp-up to reduce risk of tumor lysis syndrome
ⓘ
requires prophylaxis and monitoring for tumor lysis syndrome ⓘ |
| approvalYear | 2016 ⓘ |
| ATCCode | L01XX52 ⓘ |
| blackBoxWarning | tumor lysis syndrome ⓘ |
| chemicalStructureType | small organic molecule ⓘ |
| combinationTherapy |
used with hypomethylating agents in AML
ⓘ
used with low-dose cytarabine in AML ⓘ used with obinutuzumab in CLL ⓘ used with rituximab in CLL ⓘ |
| commonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ thrombocytopenia ⓘ |
| developer |
AbbVie
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| dosageForm | tablet ⓘ |
| drugInteraction | strong CYP3A inhibitors increase venetoclax exposure ⓘ |
| hasActiveIngredient | venetoclax NERFINISHED ⓘ |
| hasBrandName | Venclyxto NERFINISHED ⓘ |
| hasDrugClass | BCL-2 inhibitor ⓘ |
| hasInternationalNonproprietaryName | venetoclax NERFINISHED ⓘ |
| hasManufacturerCountry | United States NERFINISHED ⓘ |
| indication |
acute myeloid leukemia
ⓘ
chronic lymphocytic leukemia ⓘ first-line treatment of CLL in combination regimens ⓘ relapsed or refractory CLL ⓘ small lymphocytic lymphoma NERFINISHED ⓘ |
| indicationDetail |
CLL with or without 17p deletion
ⓘ
newly diagnosed AML in adults who are 75 years or older or who have comorbidities precluding intensive induction chemotherapy ⓘ |
| legalStatus | prescription only ⓘ |
| marketedBy |
AbbVie
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| mechanismOfAction |
inhibits the anti-apoptotic BCL-2 protein
ⓘ
promotes apoptosis of cancer cells ⓘ |
| metabolism | CYP3A substrate ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect | tumor lysis syndrome NERFINISHED ⓘ |
| targetsProtein | BCL-2 NERFINISHED ⓘ |
| therapeuticArea |
hematology
ⓘ
oncology ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.